Gut Microbiota Dynamics in Parkinsonian Mice

Area of Science:

• Neuroimmunology
• Microbiome Research
• Parkinson's Disease Pathogenesis

Background:

• Peripheral immune dysregulation is implicated in Parkinson's disease (PD), offering potential for immunotherapy.
• The gut microbiome's role in modulating immunotherapy response and its connection to the gut-brain axis in PD are not fully understood.

Purpose of the Study:

• To investigate the impact of gut microbiota dynamics in a preclinical model of Parkinson's disease receiving immunotherapy.
• To compare gut microbiota composition and structure between mice undergoing adoptive cellular therapy (ACT) and control mice.

Main Methods:

• Utilized M83 heterozygous transgenic mice treated with ACT or saline, followed by alpha-synuclein fibril injection.
• Collected fecal samples at baseline, 6, and 12 weeks post-injection for 16S rDNA sequencing and analysis.
• Employed QIIME2 and RStudio for microbial community analysis, including alpha diversity and UniFrac phylogenetic distance.

Main Results:

• Observed significant differences in the relative abundance of bacterial taxa over time between the ACT and control groups.
• No significant differences in alpha diversity were detected between groups at any time point.
• UniFrac analysis revealed distinct clustering of gut microbiomes between groups post-baseline (p = 0.002), indicating structural differences.

Conclusions:

• Gut microbiota dynamics are altered in mice receiving immunotherapy for Parkinson's disease.
• Distinct gut microbiome profiles suggest a correlation between the gut-brain axis, PD pathology, and immunotherapy outcomes.
• These findings highlight the potential influence of the gut microbiome on the efficacy of immunotherapeutic interventions in PD.